Noor Abady1, Ahmed Hamzah Mosa2 and Hamed A. H. Al-jabory3
1Depatment of Microbiology, College of veterinary medicine, AL-Qasim Green University, Babylon, Iraq,
2,3Depatment of internal and Preventive Veterinary Medicine, College of veterinary medicine, A
L-Qasim Green University, Babylon, Iraq.
*Corresponding author: ahmedvet@vet.uoqasim.edu.iq
Abstract
A new coronavirus, called SARS-CoV-2 or (2019-nCoV) with unclear background, in Hubei Province in the province of China, spread in December 2019. The coronavirus-19 pandemic sickness induced by SARS-CoV-2 (COVID-19). Various symptoms showed the existence of COVID-19. Asymptomatic/minor symptoms, serious disease, and death. The viral virus has spread worldwide and WHO has issued an international public health emergency. Suspicious communities have been divided and diagnostic/treatment protocols have been devised using clinical and epidemiological information from patients to promptly diagnose and control this highly contagious disease. The WHO invited hundreds of people early in the COVID-19 epidemic. Worldwide researchers to discover a quick diagnosis, treatment, and vaccination, but not yet FDA have authorized special antiviral therapy or vaccination. COVID-19 is now run by antiviral medicines available for improvement of symptoms and supporting treatment includes oxygen in severe situations and for infected patients, mechanical ventilation is employed. But COVID-19 turn out to be a big problem for the medical community because of the global expansion of the virus. The number has risen to 8,708,008 and 461,715, according to the newest WHO figures (in Dec 2019–June 2020), respectively. Given the situation. To date, high mortality and economic harm to different populations are important for producing Successful 2019-nCoV infection medicines and vaccinations. This is why the virus features first and foremost, its infectious routes and pathogenicity must be thoroughly understood. This review, therefore, aims mainly at Provide a summary based on the current pandemic sickness.
Keywords COVID-19, Pandemic, Vaccine
How to cite this article:
Abady, N., Mosa, A. H., and Al-jabory, H. A. H. (2021). A Review of Novel Coronavirus worldwide distribution and Public health concerned. MicrobialScienceArchives,Vol.1(1),1-4.
Copyright
This is an open-access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Abbasi, S. H., & Boroumand, M. A. (2010). Expanded network of inflammatory markers of atherogenesis: where are we now?. The open cardiovascular medicine journal, 4, 38.
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L.., & Xu, G. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international, 97(5), 829-838.
Clark, H., White, G., McCarthy, S., & Leen, B. What is the efficacy of 60% alcohol-based hand gel vs non-alcohol-based hand gel for both COVID-19 and non-COVID-19 scenarios?[v1. 0].
Contini, C., Di Nuzzo, M., Barp, N., Bonazza, A., De Giorgio, R., Tognon, M., & Rubino, S. (2020). The novel zoonotic COVID-19 pandemic: An expected global health concern. The Journal of Infection in Developing Countries, 14(03), 254-264.
De Soto, J., Hakim, S., & Boyd, F. (2020). The Pathophysiology of Virulence of the COVID-19.
Ding, S., & Liang, T. J. (2020). Is SARS-CoV-2 also an enteric pathogen with potential fecal–oral transmission? A COVID-19 virological and clinical review. Gastroenterology, 159(1), 53-61.
Ganesh, B., Rajakumar, T., Malathi, M., Manikandan, N., Nagaraj, J., Santhakumar, A., & Malik, Y. S. (2021). Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. Clinical Epidemiology and Global Health, 100694.
Giwa, A. L., & Desai, A. (2020). Novel coronavirus COVID-19: an overview for emergency clinicians. Emerg Med Pract, 22(2 Suppl 2), 1-21.
Hui, D. S., Memish, Z. A., & Zumla, A. (2014). Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Current opinion in pulmonary medicine, 20(3), 233-241.
Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S., & Syrigos, K. (2020). Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. British journal of haematology, 189(5), 846-847.
Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents, 55(3), 105924.
Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O., & Sharshir, M. D. A. (2020). Collapsing glomerulopathy in a patient with COVID-19. Kidney international reports, 5(6), 935.
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., & Albaiu, D. (2020). Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases.
Nalla, A. K., Casto, A. M., Huang, M. L. W., Perchetti, G. A., Sampoleo, R., Shrestha, L., & Greninger, A. L. (2020). Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit. Journal of clinical microbiology, 58(6), e00557-20.
Petrosillo, N., Viceconte, G., Ergonul, O., Ippolito, G., & Petersen, E. (2020). COVID-19, SARS and MERS: are they closely related?. Clinical Microbiology and Infection, 26(6), 729-734.
Rai, N. K., Ashok, A., & Akondi, B. R. (2020). Consequences of chemical impact of disinfectants: safe preventive measures against COVID-19. Critical Reviews in Toxicology, 50(6), 513-520.
Ramphul, K., & Mejias, S. G. (2020). Coronavirus disease: a review of a new threat to public health. Cureus, 12(3).
Rizzo, P., Dalla Sega, F. V., Fortini, F., Marracino, L., Rapezzi, C., & Ferrari, R. (2020). COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?.
Schett, G., Sticherling, M., & Neurath, M. F. (2020). COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nature Reviews Immunology, 20(5), 271-272.
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., & Huang, C. (2020). Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology, 5(7), 802-810.
Stawicki, S. P., Jeanmonod, R., Miller, A. C., Paladino, L., Gaieski, D. F., Yaffee, A. Q., & Garg, M. (2020). The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. Journal of global infectious diseases, 12(2), 47.
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology, 94(7), e00127-20.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama, 323(11), 1061-1069.
Wu, X., Wu, W., Pan, W., Wu, L., Liu, K., & Zhang, H. L. (2015). Acute necrotizing encephalopathy: an underrecognized clinicoradiologic disorder. Mediators of Inflammation, 2015.
Yan, C., Cui, J., Huang, L., Du, B., Chen, L., Xue, G., & Yuan, J. (2020). Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clinical Microbiology and Infection, 26(6), 773-779.
Yan, T., Xiao, R., & Lin, G. (2020). Angiotensin‐converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS‐CoV‐2: A double‐edged sword?. The FASEB Journal, 34(5), 6017-6026.
Zaim, S., Chong, J. H., Sankaranarayanan, V., & Harky, A. (2020). COVID-19 and multiorgan response. Current problems in cardiology, 45(8), 100618.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., & Cao, B. (2020). Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054-1062.
Zhu, H., Rhee, J. W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., & Wu, S. M. (2020). Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Current cardiology reports, 22(5), 1-9.
License Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
